Tuberculosis Due to Mycobacterium bovis after Alemtuzumab Administration
Open Access
- 15 July 2003
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (2) , e27-e28
- https://doi.org/10.1086/375690
Abstract
We describe a patient with relapsing B chronic lymphocytic leukemia who developed systemic bacille Calmette-Guérin infection (BCGitis) after administration of alemtuzumab (Campath-1H).Keywords
This publication has 3 references indexed in Scilit:
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.Journal of Clinical Oncology, 1997
- Campath‐1h, a humanized monoclonal antibody, in refractory rheumatoid arthritisArthritis & Rheumatism, 1995